One each in Hong Kong and Canada
Suven Life Sciences announced that the Company has secured product patents for its new chemical entities (NCEs) in Hong Kong and Canada for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2023 and 2029 respectively.Powered by Capital Market - Live News